Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age50-90
SponsorDongzhimen Hospital, Beijing

About this trial

This study is a single-center, randomized, double-blind, placebo-controlled trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.

50-90 years old, regardless of gender.

Sequential Organ Failure Assessment (SOFA) score ≥ 2.

Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.

Disqualifiers

ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.

Patients with allergies or allergic constitution to the investigational herbal medications.

Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight > 150 kg), trauma, or surgical factors.

Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fuzheng Tongfu Jiedu prescription (FZTFJD)

    Drug

    Fuzheng Tongfu Jiedu prescription (FZTFJD), a kind of Traditional Chinese medicine (TCM).Conventional Western medical treatment in accordance with the "2021 International Guidelines for the Management of Sepsis and Septic Shock." . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers.

  • Placebo

    Drug

    Fuzheng Tongfu Jiedu prescription plaebo. Conventional Western medical treatment in accordance with the "2021 International Guidelines for the Management of Sepsis and Septic Shock." . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers.

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Fuzheng Tongfu Jiedu prescription (FZTFJD)Experimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

AGI grade

As a predictor of mortality in critically ill patients, AGI grade is useful for identifying the severity of GI dysfunction. AGI grade refers to the diagnostic criteria for acute gastrointestinal injury established by the European Critical Care Society in 2012. AGI can be graded from a minimum of I to a maximum of IV. The higher the level, the more severe the gastrointestinal dysfunctionHigher AGI grade levels indicate progressively more severe conditions.

Time frame
Day0, Day3,Day7,Day14

Secondary outcomes

1

Gastrointestinal symptoms score

The gastrointestinal symptoms score will be assessed by GSRS scale. The total score of the GSRS scale ranges from 0 to 78, with higher scores indicating more severe gastrointestinal symptoms.

Time frame
Day0, Day3,Day7,Day14
2

Abdominal pressure

Abdominal pressure is measured by bladder pressure which is measured by water column method.Higher abdominal pressure levels indicate progressively more severe conditions.

Time frame
Day0, Day3,Day7,Day14
3

Abdominal circumference

At the end of exhalation and before the beginning of inhalation, the abdominal circumference through the center of the umbilical cord was measured with a soft ruler.

Time frame
Day0, Day3,Day7,Day14
4

Blood routine

Blood routine test will be determined by blood cell analyzer.White blood cells higher or lower than normal indicate a septic inflammatory state.

Time frame
Day0, Day3,Day7,Day14

Other outcomes

1

Safety index-Blood routine

Blood routine will be detected by test kit.

Time frame
Day0、 Day3、Day7、Day14
2

Safety index-liver function

The indexes related to liver function metabolism, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), direct and indirect bilirubin, albumin, prealbumin and cholinesterase, will be detected by biochemical test

Time frame
Day0、 Day3、Day7、Day14
3

Safety index-Renal function

Renal function test will be detected by test kit.

Time frame
Day0、 Day3、Day7、Day14
4

Safety index-Stool routine

Stool routine will be detected by test kit.

Time frame
Day0、 Day3、Day7、Day14

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dongzhimen Hospital, Beijing

Lead sponsor

Beijing University of Chinese Medicine

Collaborator

This trial is not recruiting at the moment. You can still explore other options: